person · Reporting owner

Shimer Julie Ann

Disclosed activity across 6 companies

Tapewire entity: 28201
SEC CIK: 0001391349

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
EarthLink Holdings, LLCELNK · Entity 178509	Director	February 27, 2017	February 27, 2017
MASIMO CORPMASI · Entity 39014	Director	May 26, 2023	May 31, 2023
NETGEAR, INC.NTGR · Entity 5389	Director	May 31, 2018	June 04, 2018
WINDSTREAM HOLDINGS, INC.WIN · Entity 166959	Director	May 01, 2018	May 03, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

EarthLink Holdings, LLC

Report date February 27, 2017 · Filed February 27, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2017-02-27 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-02-27 · Disposition to issuer · Disposed 82,327 · Balance 0 F1: Disposition pursuant to the Agreement and Plan of Merger, dated as of November 5, 2016 (the "Merger Agreement"), by and among EarthLink, Windstream Holdings Corp. ("Windstream"), Europa Merger Sub, Inc. ("Merger Sub 1") and Europa Merger Sub, LLC ("Merger Sub 2") whereby Merger Sub 1 merged with and into EarthLink with EarthLink surviving as an indirect, wholly-owned subsidiary of Windstream (the "Merger") and, immediately thereafter, EarthLink merged with and into Merger Sub 2, with Merger Sub 2 surviving as an indirect, wholly-owned subsidiary of Windstream with the Merger being a transaction exempt under Rule 16b-3(e). Upon completion of the Merger, each outstanding share of EarthLink common stock was converted into 0.818 shares of Windstream common stock and each outstanding restricted stock unit ("RSU") was assumed by Windstream and converted into 0.818 RSUs of Windstream. Pursuant to the RSU agreements, the RSUs became earned and payable upon consummation of the Merger.
Restricetd Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2017-02-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-02-27 · Disposition to issuer · Disposed 24,390 · Balance 0 F1: Disposition pursuant to the Agreement and Plan of Merger, dated as of November 5, 2016 (the "Merger Agreement"), by and among EarthLink, Windstream Holdings Corp. ("Windstream"), Europa Merger Sub, Inc. ("Merger Sub 1") and Europa Merger Sub, LLC ("Merger Sub 2") whereby Merger Sub 1 merged with and into EarthLink with EarthLink surviving as an indirect, wholly-owned subsidiary of Windstream (the "Merger") and, immediately thereafter, EarthLink merged with and into Merger Sub 2, with Merger Sub 2 surviving as an indirect, wholly-owned subsidiary of Windstream with the Merger being a transaction exempt under Rule 16b-3(e). Upon completion of the Merger, each outstanding share of EarthLink common stock was converted into 0.818 shares of Windstream common stock and each outstanding restricted stock unit ("RSU") was assumed by Windstream and converted into 0.818 RSUs of Windstream. Pursuant to the RSU agreements, the RSUs became earned and payable upon consummation of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: Disposition pursuant to the Agreement and Plan of Merger, dated as of November 5, 2016 (the "Merger Agreement"), by and among EarthLink, Windstream Holdings Corp. ("Windstream"), Europa Merger Sub, Inc. ("Merger Sub 1") and Europa Merger Sub, LLC ("Merger Sub 2") whereby Merger Sub 1 merged with and into EarthLink with EarthLink surviving as an indirect, wholly-owned subsidiary of Windstream (the "Merger") and, immediately thereafter, EarthLink merged with and into Merger Sub 2, with Merger Sub 2 surviving as an indirect, wholly-owned subsidiary of Windstream with the Merger being a transaction exempt under Rule 16b-3(e). Upon completion of the Merger, each outstanding share of EarthLink common stock was converted into 0.818 shares of Windstream common stock and each outstanding restricted stock unit ("RSU") was assumed by Windstream and converted into 0.818 RSUs of Windstream. Pursuant to the RSU agreements, the RSUs became earned and payable upon consummation of the Merger.

MASIMO CORP

Report date May 26, 2023 · Filed May 31, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,410	Reported balance After 2023-05-26 transaction · row 1 1 source row Row 1 · 2023-05-26 · Exercise / conversion · Acquired 1,435 · Balance 4,410 F1: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-05-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-05-26 · Exercise / conversion · Disposed 1,435 · Balance 0 F1: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F2: These RSUs were granted on May 26, 2022 and vested in full on May 26, 2023, the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU.

F2: These RSUs were granted on May 26, 2022 and vested in full on May 26, 2023, the first anniversary of the grant date.

NETGEAR, INC.

Report date May 31, 2018 · Filed June 04, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	34,928	Reported balance After 2018-05-31 transaction · row 1 1 source row Row 1 · 2018-05-31 · Grant · Acquired 3,308 · Balance 34,928 F1: Shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock, which will vest 100% on the date of the 2019 annual meeting of stockholders (but not less than 50 weeks from the date of grant), provided that such individual continues to serve as a member of the board of directors of NETGEAR, Inc. until such date.

Filing footnotes · ownership attribution and instrument terms

F1: Shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock, which will vest 100% on the date of the 2019 annual meeting of stockholders (but not less than 50 weeks from the date of grant), provided that such individual continues to serve as a member of the board of directors of NETGEAR, Inc. until such date.

WINDSTREAM HOLDINGS, INC.

Report date May 01, 2018 · Filed May 03, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	176,906	Reported balance After 2018-05-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-05-01 · Grant · Acquired 68,493 · Balance 176,906 F1: These shares were issued under an equity incentive plan in accordance with Rule 16b-3(d) and are subject to a substantial risk of forfeiture until vested. Shares vest on May 1, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were issued under an equity incentive plan in accordance with Rule 16b-3(d) and are subject to a substantial risk of forfeiture until vested. Shares vest on May 1, 2019.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AVANOS MEDICAL, INC.

Report date July 27, 2026 · Filed July 28, 2026

Section 16 reporting ended · disclosed 2026-07-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2026-07-27 transaction · row 1 1 source row Row 1 · 2026-07-27 · Disposition to issuer · Disposed 50,090 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the merger (the Merger), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-07-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-07-27 · Disposition to issuer · Disposed 12,003 · Balance 0 F2: Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock. F3: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings).

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the merger (the Merger), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement.

F2: Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock.

F3: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings).

Apollo Endosurgery, Inc.

Report date April 04, 2023 · Filed April 04, 2023

Section 16 reporting ended · disclosed 2023-04-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-04-04 transaction · row 1 1 source row Row 1 · 2023-04-04 · Disposition to issuer · Disposed 36,021 · Balance 0 F1: Reflects the disposition of the reporting person's 21,797 shares of Issuer common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock, was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F2: Reflects the disposition of the reporting person's 14,224 shares of Issuer RSUs upon the consummation of the Merger. Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit award granted under any Issuer Stock Plan (each, an "Issuer RSU"), whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the Merger Consideration and (2) the aggregate number of shares of Issuer Common Stock underlying such Issuer RSU, less applicable taxes and authorized deductions.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.75 · Expires 2028-08-13	Direct	Reported balance After 2023-04-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-04-04 · Disposition to issuer · Disposed 8,002 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.27 · Expires 2029-08-16	Direct	Reported balance After 2023-04-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-04-04 · Disposition to issuer · Disposed 16,536 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.86 · Expires 2031-06-17	Direct	Reported balance After 2023-04-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-04-04 · Disposition to issuer · Disposed 5,271 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2030-05-07	Direct	Reported balance After 2023-04-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-04-04 · Disposition to issuer · Disposed 28,156 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 · Expires 2032-06-14	Direct	Reported balance After 2023-04-04 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-04-04 · Disposition to issuer · Disposed 19,333 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of the reporting person's 21,797 shares of Issuer common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock, was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions.

F2: Reflects the disposition of the reporting person's 14,224 shares of Issuer RSUs upon the consummation of the Merger. Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit award granted under any Issuer Stock Plan (each, an "Issuer RSU"), whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the Merger Consideration and (2) the aggregate number of shares of Issuer Common Stock underlying such Issuer RSU, less applicable taxes and authorized deductions.

F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 27, 2026 Filed Jul 28, 2026 21:38 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	Disposition to issuerRestricted Share Units · Derivative	12,003	$25.00	$300,075.00	Disclosure SEC source: 0001606498-26-000109 · wk-form4_1785274701.xml · derivative · entry 2 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,003 shares Expires not disclosed F2 · derivative.exercise_price: Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock. F3 · price: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings). F3 · derivative.exercise_date: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings). F3 · derivative.expiration_date: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings). Read SEC document
July 27, 2026 Filed Jul 28, 2026 21:38 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	Disposition to issuerCommon Stock	50,090	$25.00	$1,252,250.00	Disclosure SEC source: 0001606498-26-000109 · wk-form4_1785274701.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the merger (the Merger), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement. Read SEC document
May 08, 2026 Filed May 12, 2026 15:35 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantRestricted Share Units · Derivative	12,003	$0.00	$0.00	Disclosure SEC source: 0001606498-26-000071 · wk-form4_1778600145.xml · derivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,003 Underlying: Common Stock · 12,003 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock. The restricted share units were issued to replace the restricted share units issued to the Reporting Person on January 2, 2025. F2 · derivative.exercise_date: The restricted share units vest on the date the Reporting Person terminates service on the Issuer's Board of Directors. F2 · derivative.expiration_date: The restricted share units vest on the date the Reporting Person terminates service on the Issuer's Board of Directors. Read SEC document
January 02, 2025 Filed Jan 6, 2025 18:46 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	12,003	$0.00	$0.00	Disclosure SEC source: 0001606498-25-000008 · wk-form4_1736189167.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,093 F1 · shares: Represents restricted share units issued to the Reporting Person on January 2, 2025 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
March 11, 2024 Filed Mar 11, 2024 21:15 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	PurchaseCommon Stock	500	$19.85	$9,925.00	Disclosure SEC source: 0001606498-24-000043 · wk-form4_1710191723.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,090 Read SEC document
January 03, 2024 Filed Jan 4, 2024 20:06 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	8,378	$0.00	$0.00	Disclosure SEC source: 0001606498-24-000008 · wk-form4_1704398805.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,590 F1 · shares: Represents restricted share units issued to the Reporting Person on January 3, 2024 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
May 26, 2023 Filed May 31, 2023 20:18 UTC	MASIMO CORP MASI · Entity 39014	Exercise / conversionRestricted Stock Units · Derivative	1,435	$0.00	$0.00	Disclosure SEC source: 0000937556-23-000123 · wf-form4_168556430325379.xml · derivative · entry 2 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F2 · derivative.exercise_date: These RSUs were granted on May 26, 2022 and vested in full on May 26, 2023, the first anniversary of the grant date. F2 · derivative.expiration_date: These RSUs were granted on May 26, 2022 and vested in full on May 26, 2023, the first anniversary of the grant date. Read SEC document
May 26, 2023 Filed May 31, 2023 20:18 UTC	MASIMO CORP MASI · Entity 39014	Exercise / conversionCommon Stock	1,435	Not disclosed	Not disclosed	Disclosure SEC source: 0000937556-23-000123 · wf-form4_168556430325379.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. Read SEC document
April 04, 2023 Filed Apr 4, 2023 19:54 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	Disposition to issuerStock Option (Right to Buy) · Derivative	19,333	Not disclosed Strike: $3.95	Not disclosed	Disclosure SEC source: 0001251769-23-000021 · wf-form4_168065243387983.xml · derivative · entry 6 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,333 shares Expires 2032-06-14 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. Read SEC document
April 04, 2023 Filed Apr 4, 2023 19:54 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	5,271	Not disclosed Strike: $8.86	Not disclosed	Disclosure SEC source: 0001251769-23-000021 · wf-form4_168065243387983.xml · derivative · entry 5 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,271 shares Expires 2031-06-17 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. Read SEC document
April 04, 2023 Filed Apr 4, 2023 19:54 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	Disposition to issuerStock Option (Right to Buy) · Derivative	28,156	Not disclosed Strike: $2.08	Not disclosed	Disclosure SEC source: 0001251769-23-000021 · wf-form4_168065243387983.xml · derivative · entry 4 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,156 shares Expires 2030-05-07 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. Read SEC document
April 04, 2023 Filed Apr 4, 2023 19:54 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	16,536	Not disclosed Strike: $3.27	Not disclosed	Disclosure SEC source: 0001251769-23-000021 · wf-form4_168065243387983.xml · derivative · entry 3 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,536 shares Expires 2029-08-16 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. Read SEC document
April 04, 2023 Filed Apr 4, 2023 19:54 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	8,002	Not disclosed Strike: $7.75	Not disclosed	Disclosure SEC source: 0001251769-23-000021 · wf-form4_168065243387983.xml · derivative · entry 2 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Sock · 8,002 shares Expires 2028-08-13 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. Read SEC document
April 04, 2023 Filed Apr 4, 2023 19:54 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	Disposition to issuerCommon Stock	36,021	Not disclosed	Not disclosed	Disclosure SEC source: 0001251769-23-000021 · wf-form4_168065243387983.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Reflects the disposition of the reporting person's 21,797 shares of Issuer common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock, was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F2 · shares: Reflects the disposition of the reporting person's 14,224 shares of Issuer RSUs upon the consummation of the Merger. Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit award granted under any Issuer Stock Plan (each, an "Issuer RSU"), whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the Merger Consideration and (2) the aggregate number of shares of Issuer Common Stock underlying such Issuer RSU, less applicable taxes and authorized deductions. F1 · price: Reflects the disposition of the reporting person's 21,797 shares of Issuer common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock, was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F2 · price: Reflects the disposition of the reporting person's 14,224 shares of Issuer RSUs upon the consummation of the Merger. Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit award granted under any Issuer Stock Plan (each, an "Issuer RSU"), whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the Merger Consideration and (2) the aggregate number of shares of Issuer Common Stock underlying such Issuer RSU, less applicable taxes and authorized deductions. Read SEC document
January 03, 2023 Filed Jan 5, 2023 14:57 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	7,008	$0.00	$0.00	Disclosure SEC source: 0001606498-23-000005 · wf-form4_167293064134736.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,212 F1 · shares: Represents restricted share units issued to the Reporting Person on January 3, 2023 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
June 14, 2022 Filed Jun 16, 2022 21:19 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	GrantStock Option (Right to Buy) · Derivative	19,333	$0.00 Strike: $3.95	$0.00	Disclosure SEC source: 0001251769-22-000057 · wf-form4_165542873057813.xml · derivative · entry 2 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,333 Underlying: Common Stock · 19,333 shares Expires 2032-06-14 Read SEC document
June 14, 2022 Filed Jun 16, 2022 21:19 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	GrantCommon Stock	14,224	$0.00	$0.00	Disclosure SEC source: 0001251769-22-000057 · wf-form4_165542873057813.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,021 F1 · shares: Represents the grant of Restricted Stock Units ("RSUs"). Each RSU provides the Reporting Person with a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the one year anniversary of the grant date. Read SEC document
May 26, 2022 Filed May 31, 2022 20:16 UTC	MASIMO CORP MASI · Entity 39014	GrantRestricted Stock Units · Derivative	1,435	$0.00	$0.00	Disclosure SEC source: 0000937556-22-000105 · wf-form4_165402818443219.xml · derivative · entry 3 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,435 Underlying: Common Stock · 1,435 shares Expires 2032-05-26 F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F3 · derivative.exercise_date: These RSUs were granted on May 26, 2022 and will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the date of grant. Read SEC document
May 26, 2022 Filed May 31, 2022 20:16 UTC	MASIMO CORP MASI · Entity 39014	Exercise / conversionRestricted Stock Units · Derivative	922	$139.34	$128,471.48	Disclosure SEC source: 0000937556-22-000105 · wf-form4_165402818443219.xml · derivative · entry 2 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 922 shares Expires 2031-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F2 · derivative.exercise_date: These RSUs were granted on May 27, 2021 and vested in full on May 26, 2022, the date of the next annual meeting of stockholders following the date of grant. Read SEC document
May 26, 2022 Filed May 31, 2022 20:16 UTC	MASIMO CORP MASI · Entity 39014	Exercise / conversionCommon Stock	922	$139.34	$128,471.48	Disclosure SEC source: 0000937556-22-000105 · wf-form4_165402818443219.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2022 Filed Jan 4, 2022 22:21 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	5,354	$0.00	$0.00	Disclosure SEC source: 0001606498-22-000002 · wf-form4_164133486055503.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,204 F1 · shares: Represents restricted share units issued to the reporting person on January 3, 2022 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
June 17, 2021 Filed Jun 21, 2021 10:51 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	GrantNon-Qualified Stock Option (right to buy) · Derivative	5,271	$8.86 Strike: $8.86	$46,701.06	Disclosure SEC source: 0001251769-21-000080 · wf-form4_162428707544760.xml · derivative · entry 2 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,965 Underlying: Common Stock · 5,271 shares Expires 2031-06-17 F1 · date: Fully vested at one year anniversary of grant date. Read SEC document
June 17, 2021 Filed Jun 21, 2021 10:51 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	GrantCommon Stock	3,888	$0.00	$0.00	Disclosure SEC source: 0001251769-21-000080 · wf-form4_162428707544760.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,797 F1 · date: Fully vested at one year anniversary of grant date. Read SEC document
May 27, 2021 Filed Jun 1, 2021 21:35 UTC	MASIMO CORP MASI · Entity 39014	GrantRestricted Stock Units · Derivative	922	$0.00	$0.00	Disclosure SEC source: 0000937556-21-000106 · wf-form4_162258333073390.xml · derivative · entry 3 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 922 Underlying: Common Stock · 922 shares Expires 2031-05-27 F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F3 · derivative.exercise_date: These RSUs were granted on May 27, 2021 and will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the date of grant. Read SEC document
May 27, 2021 Filed Jun 1, 2021 21:35 UTC	MASIMO CORP MASI · Entity 39014	Exercise / conversionRestricted Stock Units · Derivative	749	$216.79	$162,375.71	Disclosure SEC source: 0000937556-21-000106 · wf-form4_162258333073390.xml · derivative · entry 2 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 749 shares Expires 2030-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F2 · derivative.exercise_date: These RSUs were granted on May 29, 2020 and vested in full on May 27, 2021, the date of the next annual meeting of stockholders following the date of grant. Read SEC document
May 27, 2021 Filed Jun 1, 2021 21:35 UTC	MASIMO CORP MASI · Entity 39014	Exercise / conversionCommon Stock	749	$216.79	$162,375.71	Disclosure SEC source: 0000937556-21-000106 · wf-form4_162258333073390.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 04, 2021 Filed Jan 6, 2021 15:27 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	4,005	$0.00	$0.00	Disclosure SEC source: 0001606498-21-000006 · wf-form4_160994682230139.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,850 F1 · shares: Represents restricted share units issued to the reporting person on January 4, 2021 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
May 29, 2020 Filed Jun 2, 2020 21:33 UTC	MASIMO CORP MASI · Entity 39014	GrantRestricted Stock Units · Derivative	749	$0.00	$0.00	Disclosure SEC source: 0000937556-20-000129 · wf-form4_159113360126547.xml · derivative · entry 3 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 749 Underlying: Common Stock · 749 shares Expires 2030-05-29 F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F3 · derivative.exercise_date: These RSUs were granted on May 29, 2020 and will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the date of grant. Read SEC document
May 29, 2020 Filed Jun 2, 2020 21:33 UTC	MASIMO CORP MASI · Entity 39014	Exercise / conversionRestricted Stock Units · Derivative	1,304	$240.19	$313,207.76	Disclosure SEC source: 0000937556-20-000129 · wf-form4_159113360126547.xml · derivative · entry 2 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,304 shares Expires 2029-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F2 · derivative.exercise_date: These RSUs were granted on May 30, 2019 and vested in full on May 29, 2020, the date of the next annual meeting of stockholders following the date of grant. Read SEC document
May 29, 2020 Filed Jun 2, 2020 21:33 UTC	MASIMO CORP MASI · Entity 39014	Exercise / conversionCommon Stock	1,304	$240.19	$313,207.76	Disclosure SEC source: 0000937556-20-000129 · wf-form4_159113360126547.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 07, 2020 Filed May 11, 2020 17:32 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	GrantNon-Qualified Stock Option (right to buy) · Derivative	28,156	$2.08 Strike: $2.08	$58,564.48	Disclosure SEC source: 0001251769-20-000054 · wf-form4_158923273583635.xml · derivative · entry 2 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,694 Underlying: Common Stock · 28,156 shares Expires 2030-05-07 F2 · date: The shares underlying the option shall vest fully on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date. Accelerated vesting may occur in the event of a Change in Control, as that term is defined in the Apollo Endosurgery, Inc. 2017 Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option shall vest fully on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date. Accelerated vesting may occur in the event of a Change in Control, as that term is defined in the Apollo Endosurgery, Inc. 2017 Equity Incentive Plan. Read SEC document
May 07, 2020 Filed May 11, 2020 17:32 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	GrantCommon Stock	10,153	$0.00	$0.00	Disclosure SEC source: 0001251769-20-000054 · wf-form4_158923273583635.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,909 F1 · date: Represents the grant of Restricted Stock Units ("RSU"). Each RSU provides the Reporting Person with a contingent right to receive one share of the Issuer's common stock pursuant to the Apollo Endosurgery, Inc. 2017 Equity Incentive Plan. The RSUs vest fully on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through each such date. Accelerated vesting may occur in the event of a Change in Control, as that term is defined in the Apollo Endosurgery, Inc. 2017 Incentive Plan. Read SEC document
January 02, 2020 Filed Jan 8, 2020 21:18 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	5,293	$0.00	$0.00	Disclosure SEC source: 0001606498-20-000005 · wf-form4_157851827821331.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,845 F1 · shares: Represents restricted share units issued to the reporting person on January 2, 2020 pursuant to the Avanos Medical, Inc. Outside Director's Compensation Plan. Read SEC document
August 16, 2019 Filed Aug 20, 2019 16:29 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	GrantNon-Qualified Stock Option (right to buy) · Derivative	16,536	$3.27 Strike: $3.27	$54,072.72	Disclosure SEC source: 0001251769-19-000078 · wf-form4_156633292481942.xml · derivative · entry 2 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,538 Underlying: Common Stock · 16,536 shares Expires 2029-08-16 F1 · derivative.exercise_price: Fully vested at one year anniversary of grant date. Read SEC document
August 16, 2019 Filed Aug 20, 2019 16:29 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	GrantCommon Stock	5,399	$0.00	$0.00	Disclosure SEC source: 0001251769-19-000078 · wf-form4_156633292481942.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,756 F1 · date: Fully vested at one year anniversary of grant date. Read SEC document
May 30, 2019 Filed Jun 3, 2019 20:24 UTC	MASIMO CORP MASI · Entity 39014	GrantRestricted Stock Units · Derivative	1,304	$0.00	$0.00	Disclosure SEC source: 0000937556-19-000111 · wf-form4_155959348121730.xml · derivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,304 Underlying: Common Stock · 1,304 shares Expires 2029-05-30 F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F2 · derivative.exercise_date: These RSUs were granted on May 30, 2019 and will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the date of grant. Read SEC document
January 02, 2019 Filed Jan 4, 2019 14:03 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	4,248	$0.00	$0.00	Disclosure SEC source: 0001606498-19-000002 · wf-form4_154661060655885.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,552 F1 · shares: Represents restricted share units issued to the reporting person on January 2, 2019, pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
August 13, 2018 Filed Aug 15, 2018 16:07 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	GrantNon-Qualified Stock Option (right to buy) · Derivative	8,002	$7.75 Strike: $7.75	$62,015.50	Disclosure SEC source: 0001251769-18-000086 · wf-form4_153436364520935.xml · derivative · entry 2 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,002 Underlying: Common Sock · 8,002 shares Expires 2028-08-13 F1 · derivative.exercise_price: Fully vested at one year anniversary of grant date. Read SEC document
August 13, 2018 Filed Aug 15, 2018 16:07 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	GrantCommon Sock	2,357	$0.00	$0.00	Disclosure SEC source: 0001251769-18-000086 · wf-form4_153436364520935.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,357 F1 · date: Fully vested at one year anniversary of grant date. Read SEC document
May 31, 2018 Filed Jun 4, 2018 20:15 UTC	NETGEAR, INC. NTGR · Entity 5389	GrantCommon Stock	3,308	$0.00	$0.00	Disclosure SEC source: 0001122904-18-000180 · wf-form4_152814330362129.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,928 F1 · shares: Shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock, which will vest 100% on the date of the 2019 annual meeting of stockholders (but not less than 50 weeks from the date of grant), provided that such individual continues to serve as a member of the board of directors of NETGEAR, Inc. until such date. Read SEC document
May 03, 2018 Filed May 4, 2018 14:40 UTC	AVANOS MEDICAL, INC. HYH · Entity 28189	GrantCommon Stock	384	$0.00	$0.00	Disclosure SEC source: 0001606498-18-000042 · wf-form4_152544475690148.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,304 F1 · shares: Represents restricted share units issued to the reporting person on May 3, 2018 pursuant to the Halyard Health, Inc. Outside Director's Compensation Plan. Read SEC document
May 01, 2018 Filed May 3, 2018 13:19 UTC	WINDSTREAM HOLDINGS, INC. WIN · Entity 166959	GrantCommon Stock	68,493	$1.46	$99,999.78	Disclosure SEC source: 0001225208-18-008610 · doc4.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,906 F1 · security: These shares were issued under an equity incentive plan in accordance with Rule 16b-3(d) and are subject to a substantial risk of forfeiture until vested. Shares vest on May 1, 2019. Read SEC document
January 02, 2018 Filed Jan 3, 2018 22:13 UTC	AVANOS MEDICAL, INC. HYH · Entity 28189	GrantCommon Stock	2,946	$0.00	$0.00	Disclosure SEC source: 0001606498-18-000010 · wf-form4_151501759050709.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,920 F1 · shares: Represents restricted share units issued to the reporting person on January 2, 2018 pursuant to the Halyard Health, Inc. Outside Director's Compensation Plan. Read SEC document
December 28, 2017 Filed Dec 28, 2017 23:29 UTC Amendment	NETGEAR, INC. NTGR · Entity 5389	GiftCommon Stock	2,000	$0.00	$0.00	Disclosure SEC source: 0001122904-17-000361 · wf-form4a_151450373143359.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,620 F1 · date: Amend the date of the transaction F2 · kind: 2,000 shares were gifted as a charitable donation. Read SEC document
December 22, 2017 Filed Dec 27, 2017 23:47 UTC	NETGEAR, INC. NTGR · Entity 5389	GiftCommon Stock	2,000	$0.00	$0.00	Disclosure SEC source: 0001122904-17-000359 · wf-form4_151441844647225.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,620 F1 · kind: 2,000 shares were gifted as a charitable donation. Read SEC document
June 01, 2017 Filed Jun 6, 2017 00:00 UTC	NETGEAR, INC. NTGR · Entity 5389	GrantCommon Stock	4,683	$0.00	$0.00	Disclosure SEC source: 0001122904-17-000204 · wf-form4_149670720543660.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,620 F1 · shares: Shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. 100% of the restricted stock units will vest on the date of the Issuer's 2018 Annual Meeting of Stockholders. Read SEC document
May 02, 2017 Filed May 4, 2017 16:57 UTC	WINDSTREAM HOLDINGS, INC. WIN · Entity 166959	GrantCommon Stock	17,985	$5.56	$99,996.60	Disclosure SEC source: 0001225208-17-009159 · doc4.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,413 F1 · security: These shares were issued under an equity incentive plan in accordance with Rule 16b-3(d) and are subject to a substantial risk of forfeiture until vested. Shares vest on May 1, 2018. Read SEC document
March 02, 2017 Filed Mar 6, 2017 14:11 UTC	WINDSTREAM HOLDINGS, INC. WIN · Entity 166959	GrantCommon Stock	3,133	$7.52	$23,560.16	Disclosure SEC source: 0001225208-17-005592 · doc4.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,428 F1 · security: These shares were issued under an equity incentive plan in accordance with Rule 16b-3(d) and are subject to a substantial risk of forfeiture until vested. Shares vest on May 1, 2017. Read SEC document
February 27, 2017 Filed Feb 27, 2017 17:12 UTC	EarthLink Holdings, LLC ELNK · Entity 178509	Disposition to issuerRestricetd Stock Units · Derivative	24,390	Not disclosed	Not disclosed	Disclosure SEC source: 0001102541-17-000040 · primary_doc.xml · derivative · entry 2 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,390 shares Expires not disclosed F1 · security: Disposition pursuant to the Agreement and Plan of Merger, dated as of November 5, 2016 (the "Merger Agreement"), by and among EarthLink, Windstream Holdings Corp. ("Windstream"), Europa Merger Sub, Inc. ("Merger Sub 1") and Europa Merger Sub, LLC ("Merger Sub 2") whereby Merger Sub 1 merged with and into EarthLink with EarthLink surviving as an indirect, wholly-owned subsidiary of Windstream (the "Merger") and, immediately thereafter, EarthLink merged with and into Merger Sub 2, with Merger Sub 2 surviving as an indirect, wholly-owned subsidiary of Windstream with the Merger being a transaction exempt under Rule 16b-3(e). Upon completion of the Merger, each outstanding share of EarthLink common stock was converted into 0.818 shares of Windstream common stock and each outstanding restricted stock unit ("RSU") was assumed by Windstream and converted into 0.818 RSUs of Windstream. Pursuant to the RSU agreements, the RSUs became earned and payable upon consummation of the Merger. F1 · derivative.exercise_price: Disposition pursuant to the Agreement and Plan of Merger, dated as of November 5, 2016 (the "Merger Agreement"), by and among EarthLink, Windstream Holdings Corp. ("Windstream"), Europa Merger Sub, Inc. ("Merger Sub 1") and Europa Merger Sub, LLC ("Merger Sub 2") whereby Merger Sub 1 merged with and into EarthLink with EarthLink surviving as an indirect, wholly-owned subsidiary of Windstream (the "Merger") and, immediately thereafter, EarthLink merged with and into Merger Sub 2, with Merger Sub 2 surviving as an indirect, wholly-owned subsidiary of Windstream with the Merger being a transaction exempt under Rule 16b-3(e). Upon completion of the Merger, each outstanding share of EarthLink common stock was converted into 0.818 shares of Windstream common stock and each outstanding restricted stock unit ("RSU") was assumed by Windstream and converted into 0.818 RSUs of Windstream. Pursuant to the RSU agreements, the RSUs became earned and payable upon consummation of the Merger. F1 · kind: Disposition pursuant to the Agreement and Plan of Merger, dated as of November 5, 2016 (the "Merger Agreement"), by and among EarthLink, Windstream Holdings Corp. ("Windstream"), Europa Merger Sub, Inc. ("Merger Sub 1") and Europa Merger Sub, LLC ("Merger Sub 2") whereby Merger Sub 1 merged with and into EarthLink with EarthLink surviving as an indirect, wholly-owned subsidiary of Windstream (the "Merger") and, immediately thereafter, EarthLink merged with and into Merger Sub 2, with Merger Sub 2 surviving as an indirect, wholly-owned subsidiary of Windstream with the Merger being a transaction exempt under Rule 16b-3(e). Upon completion of the Merger, each outstanding share of EarthLink common stock was converted into 0.818 shares of Windstream common stock and each outstanding restricted stock unit ("RSU") was assumed by Windstream and converted into 0.818 RSUs of Windstream. Pursuant to the RSU agreements, the RSUs became earned and payable upon consummation of the Merger. F1 · price: Disposition pursuant to the Agreement and Plan of Merger, dated as of November 5, 2016 (the "Merger Agreement"), by and among EarthLink, Windstream Holdings Corp. ("Windstream"), Europa Merger Sub, Inc. ("Merger Sub 1") and Europa Merger Sub, LLC ("Merger Sub 2") whereby Merger Sub 1 merged with and into EarthLink with EarthLink surviving as an indirect, wholly-owned subsidiary of Windstream (the "Merger") and, immediately thereafter, EarthLink merged with and into Merger Sub 2, with Merger Sub 2 surviving as an indirect, wholly-owned subsidiary of Windstream with the Merger being a transaction exempt under Rule 16b-3(e). Upon completion of the Merger, each outstanding share of EarthLink common stock was converted into 0.818 shares of Windstream common stock and each outstanding restricted stock unit ("RSU") was assumed by Windstream and converted into 0.818 RSUs of Windstream. Pursuant to the RSU agreements, the RSUs became earned and payable upon consummation of the Merger. F1 · derivative.exercise_date: Disposition pursuant to the Agreement and Plan of Merger, dated as of November 5, 2016 (the "Merger Agreement"), by and among EarthLink, Windstream Holdings Corp. ("Windstream"), Europa Merger Sub, Inc. ("Merger Sub 1") and Europa Merger Sub, LLC ("Merger Sub 2") whereby Merger Sub 1 merged with and into EarthLink with EarthLink surviving as an indirect, wholly-owned subsidiary of Windstream (the "Merger") and, immediately thereafter, EarthLink merged with and into Merger Sub 2, with Merger Sub 2 surviving as an indirect, wholly-owned subsidiary of Windstream with the Merger being a transaction exempt under Rule 16b-3(e). Upon completion of the Merger, each outstanding share of EarthLink common stock was converted into 0.818 shares of Windstream common stock and each outstanding restricted stock unit ("RSU") was assumed by Windstream and converted into 0.818 RSUs of Windstream. Pursuant to the RSU agreements, the RSUs became earned and payable upon consummation of the Merger. F1 · derivative.expiration_date: Disposition pursuant to the Agreement and Plan of Merger, dated as of November 5, 2016 (the "Merger Agreement"), by and among EarthLink, Windstream Holdings Corp. ("Windstream"), Europa Merger Sub, Inc. ("Merger Sub 1") and Europa Merger Sub, LLC ("Merger Sub 2") whereby Merger Sub 1 merged with and into EarthLink with EarthLink surviving as an indirect, wholly-owned subsidiary of Windstream (the "Merger") and, immediately thereafter, EarthLink merged with and into Merger Sub 2, with Merger Sub 2 surviving as an indirect, wholly-owned subsidiary of Windstream with the Merger being a transaction exempt under Rule 16b-3(e). Upon completion of the Merger, each outstanding share of EarthLink common stock was converted into 0.818 shares of Windstream common stock and each outstanding restricted stock unit ("RSU") was assumed by Windstream and converted into 0.818 RSUs of Windstream. Pursuant to the RSU agreements, the RSUs became earned and payable upon consummation of the Merger. Read SEC document
February 27, 2017 Filed Feb 27, 2017 17:12 UTC	EarthLink Holdings, LLC ELNK · Entity 178509	Disposition to issuerCommon Stock	82,327	Not disclosed	Not disclosed	Disclosure SEC source: 0001102541-17-000040 · primary_doc.xml · nonDerivative · entry 1 Shimer Julie Ann · CIK 0001391349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Disposition pursuant to the Agreement and Plan of Merger, dated as of November 5, 2016 (the "Merger Agreement"), by and among EarthLink, Windstream Holdings Corp. ("Windstream"), Europa Merger Sub, Inc. ("Merger Sub 1") and Europa Merger Sub, LLC ("Merger Sub 2") whereby Merger Sub 1 merged with and into EarthLink with EarthLink surviving as an indirect, wholly-owned subsidiary of Windstream (the "Merger") and, immediately thereafter, EarthLink merged with and into Merger Sub 2, with Merger Sub 2 surviving as an indirect, wholly-owned subsidiary of Windstream with the Merger being a transaction exempt under Rule 16b-3(e). Upon completion of the Merger, each outstanding share of EarthLink common stock was converted into 0.818 shares of Windstream common stock and each outstanding restricted stock unit ("RSU") was assumed by Windstream and converted into 0.818 RSUs of Windstream. Pursuant to the RSU agreements, the RSUs became earned and payable upon consummation of the Merger. F1 · kind: Disposition pursuant to the Agreement and Plan of Merger, dated as of November 5, 2016 (the "Merger Agreement"), by and among EarthLink, Windstream Holdings Corp. ("Windstream"), Europa Merger Sub, Inc. ("Merger Sub 1") and Europa Merger Sub, LLC ("Merger Sub 2") whereby Merger Sub 1 merged with and into EarthLink with EarthLink surviving as an indirect, wholly-owned subsidiary of Windstream (the "Merger") and, immediately thereafter, EarthLink merged with and into Merger Sub 2, with Merger Sub 2 surviving as an indirect, wholly-owned subsidiary of Windstream with the Merger being a transaction exempt under Rule 16b-3(e). Upon completion of the Merger, each outstanding share of EarthLink common stock was converted into 0.818 shares of Windstream common stock and each outstanding restricted stock unit ("RSU") was assumed by Windstream and converted into 0.818 RSUs of Windstream. Pursuant to the RSU agreements, the RSUs became earned and payable upon consummation of the Merger. F1 · price: Disposition pursuant to the Agreement and Plan of Merger, dated as of November 5, 2016 (the "Merger Agreement"), by and among EarthLink, Windstream Holdings Corp. ("Windstream"), Europa Merger Sub, Inc. ("Merger Sub 1") and Europa Merger Sub, LLC ("Merger Sub 2") whereby Merger Sub 1 merged with and into EarthLink with EarthLink surviving as an indirect, wholly-owned subsidiary of Windstream (the "Merger") and, immediately thereafter, EarthLink merged with and into Merger Sub 2, with Merger Sub 2 surviving as an indirect, wholly-owned subsidiary of Windstream with the Merger being a transaction exempt under Rule 16b-3(e). Upon completion of the Merger, each outstanding share of EarthLink common stock was converted into 0.818 shares of Windstream common stock and each outstanding restricted stock unit ("RSU") was assumed by Windstream and converted into 0.818 RSUs of Windstream. Pursuant to the RSU agreements, the RSUs became earned and payable upon consummation of the Merger. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.